| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629797 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(5 years from now) | |
| US9770407 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(5 years from now) | |
| US8410077 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US7635773 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9750822 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9493582 | LUNDBECK PHARMS LLC | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) | |
| US11529357 | LUNDBECK PHARMS LLC | Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine |
Jan, 2040
(16 years from now) | |
Carnexiv is owned by Lundbeck Pharms Llc.
Carnexiv contains Carbamazepine.
Carnexiv has a total of 7 drug patents out of which 0 drug patents have expired.
Carnexiv was authorised for market use on 07 October, 2016.
Carnexiv is available in solution;intravenous dosage forms.
Carnexiv can be used as replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or generalized seizures.
The generics of Carnexiv are possible to be released after 31 January, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 7, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; Replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; Rep...
Dosage: SOLUTION;INTRAVENOUS
CARNEXIV family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic